StockNews.AI
ENTA
StockNews.AI
2 hrs

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

1. Enanta to hold a conference call on September 29 at 8:30 AM ET. 2. Conference will present topline results from Phase 2b RSVHR study. 3. Zelicapavir is being evaluated for treating RSV in high-risk adults. 4. Enanta focuses on drug discovery for viral infections and immunological diseases. 5. Past successes include glecaprevir for hepatitis C treatment.

7m saved
Insight
Article

FAQ

Why Bullish?

The upcoming data release could indicate positive advancements in treatment options, enhancing investor confidence. Historically, similar events have driven stock price increases for biotech firms with promising study outcomes.

How important is it?

The announcement of pivotal Phase 2b results is highly significant, as therapeutic developments can greatly influence market perception and stock performance for clinical-stage biotech companies.

Why Short Term?

The results from the conference call will have an immediate effect on sentiment and pricing, reflecting quickly due to the nature of clinical study announcements.

Related Companies

ABBVVRTXGILD
  • Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.

Conference Call and Webcast Information

The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone, please register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta's website for approximately 30 days following the event.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic and acute hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit www.enanta.com for more information.

Media and Investors Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

Related News